Acute Myeloid Leukemia in Adolescents and Young Adults Treated in Pediatric and Adult Departments in the Nordic Countries

Lovisa Wennström; Pernille Wendtland Edslev; Jonas Abrahamsson; Jan Maxwell Nørgaard; Yngvar Fløisand; Erik Forestier; Göran Gustafsson; Jesper Heldrup; Liisa Hovi; Kirsi Jahnukainen; Olafur Gisli Jonsson; Birgitte Lausen; Josefine Palle; Bernward Zeller; Erik Holmberg; Gunnar Juliusson; Dick Stockelberg; Henrik Hasle; Nordic Society of Paediatric Haematology and Oncology (NOPHO), the Danish Acute Leukemia Group, and the Swedish Acute Myeloid Leukemia Group

doi:10.1002/pbc.25713

Acute Myeloid Leukemia in Adolescents and Young Adults Treated in Pediatric and Adult Departments in the Nordic Countries

Lovisa Wennström, Pernille Wendtland Edslev, Jonas Abrahamsson, Jan Maxwell Nørgaard, Yngvar Fløisand, Erik Forestier, Göran Gustafsson, Jesper Heldrup, Liisa Hovi, Kirsi Jahnukainen, Olafur Gisli Jonsson, Birgitte Lausen, Josefine Palle, Bernward Zeller, Erik Holmberg, Gunnar Juliusson, Dick Stockelberg, Henrik Hasle, Nordic Society of Paediatric Haematology and Oncology (NOPHO), the Danish Acute Leukemia Group, and the Swedish Acute Myeloid Leukemia Group

Afdeling for Børn og Unge

19 Citationer (Scopus)

Abstract

BACKGROUND: Studies on adolescents and young adults with acute lymphoblastic leukemia suggest better results when using pediatric protocols for adult patients, while corresponding data for acute myeloid leukemia (AML) are limited.

PROCEDURE: We investigated disease characteristics and outcome for de novo AML patients 10-30 years old treated in pediatric or adult departments. We included 166 patients 10-18 years of age with AML treated according to the pediatric NOPHO-protocols (1993-2009) compared with 253 patients aged 15-30 years treated in hematology departments (1996-2009) in the Nordic countries.

RESULTS: The incidence of AML was 4.9/million/year for the age group 10-14 years, 6.5 for 15-18 years, and 6.9 for 19-30 years. Acute promyelocytic leukemia (APL) was more frequent in adults and in females of all ages. Pediatric patients with APL had similar overall survival as pediatric patients without APL. Overall survival at 5 years was 60% (52-68%) for pediatric patients compared to 65% (58-70%) for adult patients. Cytogenetics and presenting white blood cell count were the only independent prognostic factors for overall survival. Age was not an independent prognostic factor.

CONCLUSIONS: No difference was found in outcome for AML patients age 10-30 years treated according to pediatric as compared to adult protocols. Pediatr Blood Cancer 2015; 9999:1-10 © 2015 Wiley Periodicals, Inc.

Originalsprog	Engelsk
Tidsskrift	Pediatric Blood & Cancer
Vol/bind	63
Udgave nummer	1
Sider (fra-til)	83-92
Antal sider	10
ISSN	1545-5009
DOI	https://doi.org/10.1002/pbc.25713
Status	Udgivet - jan. 2016

Adgang til dokumentet

10.1002/pbc.25713

Citationsformater

Wennström, L., Edslev, P. W., Abrahamsson, J., Nørgaard, J. M., Fløisand, Y., Forestier, E., Gustafsson, G., Heldrup, J., Hovi, L., Jahnukainen, K., Jonsson, O. G., Lausen, B., Palle, J., Zeller, B., Holmberg, E., Juliusson, G., Stockelberg, D., Hasle, H., & Nordic Society of Paediatric Haematology and Oncology (NOPHO), the Danish Acute Leukemia Group, and the Swedish Acute Myeloid Leukemia Group (2016). Acute Myeloid Leukemia in Adolescents and Young Adults Treated in Pediatric and Adult Departments in the Nordic Countries. Pediatric Blood & Cancer, 63(1), 83-92. https://doi.org/10.1002/pbc.25713

Wennström, L, Edslev, PW, Abrahamsson, J, Nørgaard, JM, Fløisand, Y, Forestier, E, Gustafsson, G, Heldrup, J, Hovi, L, Jahnukainen, K, Jonsson, OG, Lausen, B, Palle, J, Zeller, B, Holmberg, E, Juliusson, G, Stockelberg, D, Hasle, H & Nordic Society of Paediatric Haematology and Oncology (NOPHO), the Danish Acute Leukemia Group, and the Swedish Acute Myeloid Leukemia Group 2016, 'Acute Myeloid Leukemia in Adolescents and Young Adults Treated in Pediatric and Adult Departments in the Nordic Countries', Pediatric Blood & Cancer, bind 63, nr. 1, s. 83-92. https://doi.org/10.1002/pbc.25713

@article{2eff7da11e7a45998dcf5b59fa2f5f06,

title = "Acute Myeloid Leukemia in Adolescents and Young Adults Treated in Pediatric and Adult Departments in the Nordic Countries",

abstract = "BACKGROUND: Studies on adolescents and young adults with acute lymphoblastic leukemia suggest better results when using pediatric protocols for adult patients, while corresponding data for acute myeloid leukemia (AML) are limited.PROCEDURE: We investigated disease characteristics and outcome for de novo AML patients 10-30 years old treated in pediatric or adult departments. We included 166 patients 10-18 years of age with AML treated according to the pediatric NOPHO-protocols (1993-2009) compared with 253 patients aged 15-30 years treated in hematology departments (1996-2009) in the Nordic countries.RESULTS: The incidence of AML was 4.9/million/year for the age group 10-14 years, 6.5 for 15-18 years, and 6.9 for 19-30 years. Acute promyelocytic leukemia (APL) was more frequent in adults and in females of all ages. Pediatric patients with APL had similar overall survival as pediatric patients without APL. Overall survival at 5 years was 60% (52-68%) for pediatric patients compared to 65% (58-70%) for adult patients. Cytogenetics and presenting white blood cell count were the only independent prognostic factors for overall survival. Age was not an independent prognostic factor.CONCLUSIONS: No difference was found in outcome for AML patients age 10-30 years treated according to pediatric as compared to adult protocols. Pediatr Blood Cancer 2015; 9999:1-10 {\textcopyright} 2015 Wiley Periodicals, Inc.",

author = "Lovisa Wennstr{\"o}m and Edslev, {Pernille Wendtland} and Jonas Abrahamsson and N{\o}rgaard, {Jan Maxwell} and Yngvar Fl{\o}isand and Erik Forestier and G{\"o}ran Gustafsson and Jesper Heldrup and Liisa Hovi and Kirsi Jahnukainen and Jonsson, {Olafur Gisli} and Birgitte Lausen and Josefine Palle and Bernward Zeller and Erik Holmberg and Gunnar Juliusson and Dick Stockelberg and Henrik Hasle and {Nordic Society of Paediatric Haematology and Oncology (NOPHO), the Danish Acute Leukemia Group, and the Swedish Acute Myeloid Leukemia Group}",

note = "{\textcopyright} 2015 Wiley Periodicals, Inc.",

year = "2016",

month = jan,

doi = "10.1002/pbc.25713",

language = "English",

volume = "63",

pages = "83--92",

journal = "Pediatric Blood & Cancer",

issn = "1545-5009",

publisher = "Wiley",

number = "1",

}

TY - JOUR

T1 - Acute Myeloid Leukemia in Adolescents and Young Adults Treated in Pediatric and Adult Departments in the Nordic Countries

AU - Wennström, Lovisa

AU - Edslev, Pernille Wendtland

AU - Abrahamsson, Jonas

AU - Nørgaard, Jan Maxwell

AU - Fløisand, Yngvar

AU - Forestier, Erik

AU - Gustafsson, Göran

AU - Heldrup, Jesper

AU - Hovi, Liisa

AU - Jahnukainen, Kirsi

AU - Jonsson, Olafur Gisli

AU - Lausen, Birgitte

AU - Palle, Josefine

AU - Zeller, Bernward

AU - Holmberg, Erik

AU - Juliusson, Gunnar

AU - Stockelberg, Dick

AU - Hasle, Henrik

AU - Nordic Society of Paediatric Haematology and Oncology (NOPHO), the Danish Acute Leukemia Group, and the Swedish Acute Myeloid Leukemia Group

PY - 2016/1

Y1 - 2016/1

N2 - BACKGROUND: Studies on adolescents and young adults with acute lymphoblastic leukemia suggest better results when using pediatric protocols for adult patients, while corresponding data for acute myeloid leukemia (AML) are limited.PROCEDURE: We investigated disease characteristics and outcome for de novo AML patients 10-30 years old treated in pediatric or adult departments. We included 166 patients 10-18 years of age with AML treated according to the pediatric NOPHO-protocols (1993-2009) compared with 253 patients aged 15-30 years treated in hematology departments (1996-2009) in the Nordic countries.RESULTS: The incidence of AML was 4.9/million/year for the age group 10-14 years, 6.5 for 15-18 years, and 6.9 for 19-30 years. Acute promyelocytic leukemia (APL) was more frequent in adults and in females of all ages. Pediatric patients with APL had similar overall survival as pediatric patients without APL. Overall survival at 5 years was 60% (52-68%) for pediatric patients compared to 65% (58-70%) for adult patients. Cytogenetics and presenting white blood cell count were the only independent prognostic factors for overall survival. Age was not an independent prognostic factor.CONCLUSIONS: No difference was found in outcome for AML patients age 10-30 years treated according to pediatric as compared to adult protocols. Pediatr Blood Cancer 2015; 9999:1-10 © 2015 Wiley Periodicals, Inc.

AB - BACKGROUND: Studies on adolescents and young adults with acute lymphoblastic leukemia suggest better results when using pediatric protocols for adult patients, while corresponding data for acute myeloid leukemia (AML) are limited.PROCEDURE: We investigated disease characteristics and outcome for de novo AML patients 10-30 years old treated in pediatric or adult departments. We included 166 patients 10-18 years of age with AML treated according to the pediatric NOPHO-protocols (1993-2009) compared with 253 patients aged 15-30 years treated in hematology departments (1996-2009) in the Nordic countries.RESULTS: The incidence of AML was 4.9/million/year for the age group 10-14 years, 6.5 for 15-18 years, and 6.9 for 19-30 years. Acute promyelocytic leukemia (APL) was more frequent in adults and in females of all ages. Pediatric patients with APL had similar overall survival as pediatric patients without APL. Overall survival at 5 years was 60% (52-68%) for pediatric patients compared to 65% (58-70%) for adult patients. Cytogenetics and presenting white blood cell count were the only independent prognostic factors for overall survival. Age was not an independent prognostic factor.CONCLUSIONS: No difference was found in outcome for AML patients age 10-30 years treated according to pediatric as compared to adult protocols. Pediatr Blood Cancer 2015; 9999:1-10 © 2015 Wiley Periodicals, Inc.

U2 - 10.1002/pbc.25713

DO - 10.1002/pbc.25713

M3 - Journal article

C2 - 26281822

SN - 1545-5009

VL - 63

SP - 83

EP - 92

JO - Pediatric Blood & Cancer

JF - Pediatric Blood & Cancer

IS - 1

ER -

Acute Myeloid Leukemia in Adolescents and Young Adults Treated in Pediatric and Adult Departments in the Nordic Countries

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater